Triage of HPV positive women in cervical cancer screening

Journal of Clinical Virology

Volumn 76, Issue , 2016, Pages S49-S55

  Wentzensen, Nicolas ^a   Schiffman, Mark ^a   Palmer, Timothy ^b   Arbyn, Marc ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

Cervical cancer screening; Cytology; HPV; Methylation; P16 Ki 67; Triage

Indexed keywords

KI 67 ANTIGEN; PROTEIN E6; PROTEIN P16; VIRUS DNA;

CANCER SCREENING; COLPOSCOPY; CYTOPATHOLOGY; GENOTYPE; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; METHYLATION; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLASSIFICATION; COMPLICATION; DNA METHYLATION; EARLY CANCER DIAGNOSIS; EMERGENCY HEALTH SERVICE; FEMALE; GENETICS; GENOTYPING TECHNIQUE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; ISOLATION AND PURIFICATION; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; RISK FACTOR; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; DNA METHYLATION; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; TRIAGE; UTERINE CERVICAL NEOPLASMS;

EID: 84960468575     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.11.015     Document Type: Review

References (68)

1. Arbyn M., Raifu A.O., Weiderpass E., Bray F., Anttila A. Trends of cervical cancer mortality in the member states of the European Union. Eur. J. Cancer 2009, 45:2640-2648. (Oxford, England: 1990).
2. Laara E., Day N.E., Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet (Lond. Engl.) 1987, 1:1247-1249.
3. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., Wacholder S. Human papillomavirus and cervical cancer. Lancet (Lond. Engl.) 2007, 370:890-907.
4. Schiffman M., Wentzensen N., Wacholder S., Kinney W., Gage J.C., Castle P.E. Human papillomavirus testing in the prevention of cervical cancer. J. Natl. Cancer Inst. 2011, 103:368-383.
5. McCredie M.R., Sharples K.J., Paul C., Baranyai J., Medley G., Jones R.W., et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008, 9:425-434.
6. Lowy D.R., Schiller J.T. Reducing HPV-associated cancer globally. Cancer Prev. Res. (Phila. Pa) 2012, 5:18-23.
7. Joura E.A., Giuliano A.R., Iversen O.E., Bouchard C., Mao C., Mehlsen J., et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N. Engl. J. Med. 2015, 372:711-723.
8. Iftner T., Becker S., Neis K.J., Castanon A., Iftner A., Holz B., et al. Head-to-head comparison of the RNA-based aptima human papillomavirus (HPV) assay and the DNA-based hybrid capture 2HPV test in a routine screening population of women aged 30-60 years in Germany. J. Clin. Microbiol. 2015, 53:2509-2516.
9. Arbyn M., Ronco G., Cuzick J., Wentzensen N., Castle P.E. How to evaluate emerging technologies in cervical cancer screening?. Int. J. Cancer 2009, 125:2489-2496.
10. Massad L.S., Einstein M.H., Huh W.K., Katki H.A., Kinney W.K., Schiffman M., et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J. Low. Genit. Tract Dis. 2013, 17:S1-27.
11. Kinney W.K., Manos M.M., Hurley L.B., Ransley J.E. Where is the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses. Obstet. Gynecol. 1998, 91:973-976.
12. Castle P.E., Sideri M., Jeronimo J., Solomon D., Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am. J. Obstet. Gynecol. 2007, 197:e1-e6. 356.
13. ASCUS-LSIL Triage Study (ALTS) Group A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am. J. Obstet. Gynecol. 2003, 188:1393-1400.
14. ASCUS-LSIL Triage Study (ALTS) Group Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am. J. Obstet. Gynecol. 2003, 188:1383-1392.
15. Wright T.C., Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J. Low. Genit. Tract Dis. 2007, 11:201-222.
16. Arbyn M., Anttila A., Jordan J., Ronco G., Schenck U., Segnan N., et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition?summary document. Ann. Oncol. 2010, 21:448-458.
17. Kelly R.S., Patnick J., Kitchener H.C., Moss S.M. HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the sentinel sites study. Br. J. Cancer 2011, 105:983-988.
18. Katki H.A., Schiffman M., Castle P.E., Fetterman B., Poitras N.E., Lorey T., et al. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J. Low. Genit. Tract Dis. 2013, 17:S28-S35.
19. Arbyn M., Roelens J., Martin-Hirsch P., Leeson S., Wentzensen N. Use of HC2 to triage women with borderline and mild dyskaryosis in the UK. Br. J. Cancer 2011, 105:877-880.
20. Saslow D., Solomon D., Lawson H.W., Killackey M., Kulasingam S.L., Cain J., et al. American cancer society, american society for colposcopy and cervical pathology, and american society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer. CA: Cancer J. Clin. 2012, 62:147-172.
21. Stampler K.M., Dunton C.J. Cervical neoplasia guidelines: United States and europe compared. J. Low. Genit. Tract Dis. 2010, 14:142-147.
22. Wentzensen N., Schiffman M. Filling a gap in cervical cancer screening programmes. Lancet Oncol. 2014, 15:249-251.
23. Karsa L., Arbyn M., Vuyst H.D., Dillner J., Dillner L., Franceschi S., et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res. 2015.
24. Arbyn M., Ronco G., Anttila A., Meijer C.J., Poljak M., Ogilvie G., et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012, 30(Suppl. 5):F88-F99.
25. Gage J.C., Schiffman M., Katki H.A., Castle P.E., Fetterman B., Wentzensen N., et al. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. J. Natl. Cancer Inst. 2014, 106.
26. Arbyn M., Roelens J., Simoens C., Buntinx F., Paraskevaidis E., Martin-Hirsch P.P., et al. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions. Cochrane Database Syst. Rev. 2013, 3. Cd008054.
27. Dijkstra M.G., Snijders P.J., Arbyn M., Rijkaart D.C., Berkhof J., Meijer C.J. Cervical cancer screening: on the way to a shift from cytology to full molecular screening. Ann. Oncol. 2014, 25:927-935.
28. Bergeron C., Giorgi-Rossi P., Cas F., Schiboni M.L., Ghiringhello B., Dalla Palma P., et al. Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial. J. Natl. Cancer Inst. 2015, 107.
29. Richardson L.A., El-Zein M., Ramanakumar A.V., Ratnam S., Sangwa-Lugoma G., Longatto-Filho A., et al. HPV DNA testing with cytology triage in cervical cancer screening: influence of revealing HPV infection status. Cancer Cytopathol. 2015, (Epub ahead of print).
30. Wright T.C., Stoler M.H., Behrens C.M., Sharma A., Zhang G., Wright T.L. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol. Oncol. 2015, 136:189-197.
31. Schiffman M., Glass A.G., Wentzensen N., Rush B.B., Castle P.E., Scott D.R., et al. A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser cohort study. Cancer Epidemiol. Biomarkers Prev. 2011, 20:1398-1409.
32. de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010, 11:1048-1056.
33. Castle P.E., Stoler M.H., Wright T.C., Sharma A., Wright T.L., Behrens C.M. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011, 12:880-890.
34. Dijkstra M.G., van Niekerk D., Rijkaart D.C., van Kemenade F.J., Heideman D.A., Snijders P.J., et al. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy. Cancer Epidemiol. Biomarkers Prev. 2014, 23:55-63.
35. Castle P.E., Cuzick J., Stoler M.H., Wright T.C., Reid J.L., Dockter J., et al. Detection of human papillomavirus 16, 18, and 45 in women with ASC-US cytology and the risk of cervical precancer: results from the CLEAR HPV study. Am. J. Clin. Pathol. 2015, 143:160-167.
36. Einstein M.H., Martens M.G., Garcia F.A., Ferris D.G., Mitchell A.L., Day S.P., et al. Clinical validation of the cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology. Gynecol. Oncol. 2010, 118:116-122.
37. Wright T.C., Stoler M.H., Agreda P.M., Beitman G.H., Gutierrez E.C., Harris J.M., et al. Clinical performance of the BD Onclarity HPV assay using an adjudicated cohort of BD SurePath liquid-based cytology specimens. Am. J. Clin. Pathol. 2014, 142:43-50.
38. Einstein M.H., Smith K.M., Davis T.E., Schmeler K.M., Ferris D.G., Savage A.H., et al. Clinical evaluation of the cartridge-based GeneXpert human papillomavirus assay in women referred for colposcopy. J. Clin. Microbiol. 2014, 52:2089-2095.
39. Hesselink A.T., Meijer C.J., Poljak M., Berkhof J., van Kemenade F.J., van der Salm M.L., et al. Clinical validation of the abbott realtime high risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening. J. Clin. Microbiol. 2013, 51:2409-2410.
40. Arbyn M., Snijders P.J., Meijer C.J., Berkhof J., Cuschieri K., Kocjan B.J., et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?. Clin. Microbiol. Infect. 2015, 21:817-826.
41. Huh W.K., Sideri M., Stoler M., Zhang G., Feldman R., Behrens C.M. Relevance of random biopsy at the transformation zone when colposcopy is negative. Obstet. Gynecol. 2014, 124:670-678.
42. Bergeron C., Ronco G., Reuschenbach M., Wentzensen N., Arbyn M., Stoler M., et al. The clinical impact of using p16(INK4a) immunochemistry in cervical histopathology and cytology: an update of recent developments. Int. J. Cancer J. Int. Cancer 2015, 136:2741-2751.
43. Carozzi F., Confortini M., Dalla Palma P., Del Mistro A., Gillio-Tos A., De Marco L., et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 2008, 9:937-945.
44. Carozzi F., Gillio-Tos A., Confortini M., Del Mistro A., Sani C., De Marco L., et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 2013, 14:168-176.
45. Wentzensen N., Schwartz L., Zuna R.E., Smith K., Mathews C., Gold M.A., et al. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin. Cancer Res. 2012, 18:4154-4162.
46. Wentzensen N., Fetterman B., Tokugawa D., Schiffman M., Castle P.E., Wood S.N., et al. Interobserver reproducibility and accuracy of p16/Ki-67 dual-stain cytology in cervical cancer screening. Cancer Cytopathol. 2014, 122:914-920.
47. Allia E., Ronco G., Coccia A., Luparia P., Macri L., Fiorito C., et al. Interpretation of p16(INK4a)/Ki-67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology. Cancer Cytopathol. 2015, 123:212-218.
48. Petry K.U., Schmidt D., Scherbring S., Luyten A., Reinecke-Luthge A., Bergeron C., et al. Triaging pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 dual-stained cytology. Gynecol. Oncol. 2011, 121:505-509.
49. Wentzensen N., Fetterman B., Castle P.E., Schiffman M., Wood S.N., Stiemerling E., et al. p16/Ki -67 dual stain cytology for detection of cervical precancer in HPV-positive women. J. Natl. Cancer Inst. 2015, 107.
50. Grabe N., Lahrmann B., Pommerencke T., von Knebel Doeberitz M., Reuschenbach M., Wentzensen N. A virtual microscopy system to scan, evaluate and archive biomarker enhanced cervical cytology slides. Cell. Oncol. 2010, 32:109-119.
51. Lahrmann B., Valous N.A., Eisenmann U., Wentzensen N., Grabe N. Semantic focusing allows fully automated single-layer slide scanning of cervical cytology slides. PLoS One 2013, 8:e61441.
52. Bierkens M., Hesselink A.T., Meijer C.J., Heideman D.A., Wisman G.B., van der Zee A.G., et al. CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. Int. J. Cancer 2013, 133:1293-1299.
53. De Strooper L.M., van Zummeren M., Steenbergen R.D., Bleeker M.C., Hesselink A.T., Wisman G.B., et al. CADM1, MAL and miR124-2 methylation analysis in cervical scrapes to detect cervical and endometrial cancer. J. Clin. Pathol. 2014, 67:1067-1071.
54. Verhoef V.M., Bosgraaf R.P., van Kemenade F.J., Rozendaal L., Heideman D.A., Hesselink A.T., et al. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol. 2014, 15:315-322.
55. De Strooper L.M., Meijer C.J., Berkhof J., Hesselink A.T., Snijders P.J., Steenbergen R.D., et al. Methylation analysis of the FAM19A4 gene in cervical scrapes is highly efficient in detecting cervical carcinomas and advanced CIN2/3 lesions. Cancer Prev. Res. (Phila. Pa) 2014, 7:1251-1257.
56. Vasiljevic N., Scibior-Bentkowska D., Brentnall A.R., Cuzick J., Lorincz A.T. Credentialing of DNA methylation assays for human genes as diagnostic biomarkers of cervical intraepithelial neoplasia in high-risk HPV positive women. Gynecol. Oncol. 2014, 132:709-714.
57. Wentzensen N., Sun C., Ghosh A., Kinney W., Mirabello L., Wacholder S., et al. Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J. Natl. Cancer Inst. 2012, 104:1738-1749.
58. Clarke M.A., Wentzensen N., Mirabello L., Ghosh A., Wacholder S., Harari A., et al. Human papillomavirus DNA methylation as a potential biomarker for cervical cancer. Cancer Epidemiol. Biomarkers Prev. 2012, 21:2125-2137.
59. Mirabello L., Sun C., Ghosh A., Rodriguez A.C., Schiffman M., Wentzensen N., et al. Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population. J. Natl. Cancer Inst. 2012, 104:556-565.
60. Arbyn M., Verdoodt F., Snijders P.J., Verhoef V.M., Suonio E., Dillner L., et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 2014, 15:172-183.
61. Zhao F.H., Jeronimo J., Qiao Y.L., Schweizer J., Chen W., Valdez M., et al. An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China. Cancer Prev. Res. (Phila. Pa) 2013, 6:938-948.
62. Qiao Y.L., Jeronimo J., Zhao F.H., Schweizer J., Chen W., Valdez M., et al. Lower cost strategies for triage of human papillomavirus DNA-positive women. Int. J. Cancer 2014, 134:2891-2901.
63. Luhn P., Houldsworth J., Cahill L., Schiffman M., Castle P.E., Zuna R.E., et al. Chromosomal gains measured in cytology samples from women with abnormal cervical cancer screening results. Gynecol. Oncol. 2013, 130:595-600.
64. Alaghehbandan R., Fontaine D., Bentley J., Escott N., Ghatage P., Lear A., et al. Performance of ProEx C and PreTect HPV-proofer E6/E7 mRNA tests in comparison with the hybrid capture 2HPV DNA test for triaging ASCUS and LSIL cytology. Diagn. Cytopathol. 2013, 41:767-775.
65. Arbyn M., Roelens J., Cuschieri K., Cuzick J., Szarewski A., Ratnam S., et al. The APTIMA HPV assay versus the hybrid capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. Int. J. Cancer 2013, 132:101-108.
66. Sahasrabuddhe V.V., Luhn P., Wentzensen N. Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts. Future Microbiol. 2011, 6:1083-1098.
67. Wentzensen N., Walker J.L., Gold M.A., Smith K.M., Zuna R.E., Mathews C., et al. Multiple biopsies and detection of cervical cancer precursors at colposcopy. J. Clin. Oncol. 2015, 33:83-89.
68. Arbyn M., Andersson K., Bergeron C., Bogers J.P., von Knebel-Doebertitz M., Dillner J. Cervical cytology biobanks as a resource for molecular epidemiology. Methods Mol. Biol. (Clifton, N. J.) 2011, 675:279-298.